Clinical Study on the Treatment of Stage IV Gastric Cancer with De-Walled Ganoderma Spore Powder and Chemotherapy
- Conditions
- Gastric Cancer
- Registration Number
- ITMCTR2000003564
- Lead Sponsor
- The First Affiliated Hospital of Zhejiang Chinese Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. It is in accordance with the diagnostic criteria in the diagnostic and therapeutic specifications for gastric cancer (2018 Edition), according to the American Joint Committee on cancer (AJCC) / International Union against cancer (iajcc), According to the TNM staging system of gastric cancer, the patients who were diagnosed as stage IV by pathology or cytology and received chemotherapy or relapsed gastric cancer but did not receive systemic chemotherapy;
2. Patients with at least one measurable lesion according to recist1.1 standard;
3. Patients older than 18 years old, regardless of gender;
4. Patients with good general condition, KPS > 60 and expected survival time > 3 months;
5. The functional level of main organs meets the following standards:
(1) The blood routine examination standard should meet: WBC >= 4.0 * 10^9 / L or ANC >= 1.5 * 10^9 / L, PLT >= 80 * 10^9 / L, Hb >= 90 g / L
(2) Biochemical examination should meet the following criteria: TBIL < 1.5 * ULN, alt, AST < 2.5 * ULN, patients with liver metastasis can be < 5 * ULN, bun and Cr <= 1 * ULN or endogenous creatinine clearance rate >= 50ml / min (Cockcroft Gault formula);
6. The subjects volunteered to participate in the study, signed the informed consent form, had good compliance and cooperated with the follow-up.
1. Patients with other tumor history within 5 years;
2. Patients complicated with any acute or chronic diseases or mental disorders or laboratory examination abnormalities, which may increase the risk of participating in the study or study drug use, or affect the research results, and the patients are judged to be not suitable for the study. These include:
(1) Uncontrolled hypertension, unstable angina, myocardial infarction, or symptomatic congestive heart failure or uncontrollable arrhythmias in the past 12 months. ECG showed obvious ischemic changes;
(2) The active period of bacterial, fungal or viral infection;
(3) Having dementia or major mental state changes that make them unable to understand or express informed consent;
3. Pregnant or lactating patients;
4. Patients who were considered unsuitable to participate in the trial;
5. The researcher judges other situations that may affect the research progress and result judgment.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression Free Survival;
- Secondary Outcome Measures
Name Time Method Systemic State Evaluation;One-year survival rate;Overall Survival;Intestinal flora analysis;Quality of life;TCM syndrome score of gastric cancer;Chemotherapy completion rate;